lung cancer

Showing 15 posts of 185 posts found.


Genentech shares phase 3 results for ALK-positive early-stage lung cancer treatment

September 1, 2023
Research and Development Genentech, NSCLC, Oncology, clinical trials, lung cancer

Roche’s Genentech has announced that the phase 3 ALINA trial assessing Alecensa, compared with platinum-based chemotherapy for the treatment of …


AstraZeneca’s lung cancer drug gains EU approval

May 28, 2021
Medical Communications AstraZeneca, EU, lung cancer, oncology

AstraZeneca’s Tagrisso (osimertinib) has been approved in the EU for the adjuvant treatment of adult patients with early-stage (IB, II …


Novartis’ canakinumab fails to improve lung cancer survival in Phase III study

March 9, 2021
Manufacturing and Production Cancer, Novartis, lung cancer

Novartis has announced that the Phase III CANOPY-2 study evaluating canakinumab, an inhibitor of interleukin-1beta (IL-1β), in combination with the chemotherapy agent …

Opdivo scores NICE recommendation in two non-small cell lung cancer indications

September 17, 2020
Sales and Marketing NICE, lung cancer, opdivo

NICE has announced its recommendation of Bristol-Myers Squibb’s blockbuster immunotherapy drug Opdivo (nivolumab) for the treatment of two non-small cell …


Genetech scores sixth FDA approval in lung cancer with Gavreto

September 7, 2020
Sales and Marketing Cancer, FDA, Genentech, lung cancer

Genentech’s once-daily oral therapy Gavreto (pralsetinib) has secured FDA backing in the treatment of metastatic rearranged during transfection (RET) fusion-positive …

FDA approval for Jazz and PharmaMar’s Zepzelca in metastatic small cell lung cancer

June 17, 2020
Manufacturing and Production, Research and Development, Sales and Marketing Cancer, FDA, PharmaMar, Zepzelca, jazz pharma, lung cancer

The FDA has awarded approval to Jazz Pharma and PharmaMar for Zepzelca (lurbinectedin) as a treatment for metastatic small cell …

NICE greenlights Roche’s Rozlytrek for ROS1+ advanced non-small cell lung cancer

June 15, 2020
Sales and Marketing NICE, Roche, Rozlytrek, UK, lung cancer

Roche’s Rozlytrek (entrectinib) has secured recommendation for NHS use in England and Wales after NICE backed the drug in final …

NICE reverses previous stance to recommend Roche’s Tecentriq in extensive-stage small-cell lung cancer

May 27, 2020
Research and Development, Sales and Marketing NICE, Roche, lung cancer, tecentriq

NHS patients with treatment-naïve extensive-stage small-cell lung cancer (ES-SCLC) in England and Wales will soon have access to a new …


Phase 3 Libtayo monotherapy trial halted early due to strong benefit in advanced non-small cell lung cancer

April 29, 2020
Research and Development Cancer, Libtayo, Regeneron, Sanofi, lung cancer

A Phase 3 study of Sanofi and Regeneron’s Libtayo (cemiplimab) as a monotherapy for advanced or metastatic non-small cell lung …


FDA immunotherapy first with the approval of AZ’s Imfinzi in first-line extensive-stage small cell lung cancer

March 30, 2020
Sales and Marketing AstraZeneca, Cancer, FDA, Imfinzi, lung cancer, pharma

AstraZeneca has seized FDA approval for its immune checkpoint inhibitor Imfinzi (durvalumab) in the first-line treatment of extensive-stage small cell …


Positive CHMP approval for Takeda’s Alunbrig in ALK+ advanced non-small lung cancer

March 4, 2020
Research and Development CHMP, EMA, Takeda, lung cancer, pharma

Takeda’s Alunbrig (brigatinib) has been recommended for approval by the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human …


BMS pulls Opdivo+Yervoy combo in EU for advanced non-small cell lung cancer

February 3, 2020
Sales and Marketing BMS, Cancer, Europe, Yervoy, lung cancer, opdivo

Bristol-Myers Squibb has confirmed it has withdrawn its application with the European Commission for its combination of Opdivo (nivolumab) and …


Healthy cells in lungs can repair the damage from smoking

January 30, 2020
Business Services Cancer smoking, cigarettes, lung cancer, lungs, smoking

Human lungs have the ‘magical’ ability to repair the cancerous mutations caused by smoking cigarettes, but only if people quit …


Largest drop ever in US cancer mortality rates, new study shows

January 9, 2020
Business Services Cancer, brain cancer, lung cancer, prostate cancer

The overall cancer mortality rate in the US fell by 2.2% from 2016 to 2017, the largest ever annual decline …


Transgene ceases development of failed advanced non-squamous non-small cell lung cancer immunotherapy candidate

December 16, 2019
Research and Development, Sales and Marketing Cancer, Transgene, lung cancer, pharma

Cancer immunotherapeutics firm Transgene has confirmed that it is to terminate further development of its TG4010 candidate in the first-line …

Latest content